Nanoparticles-based therapeutics for the management of bacterial infections: A special emphasis on FDA approved products and clinical trials.

导出 LinkOut

翻译打印收藏纠错

作者： Fatemeh,Aflakian ^[1] ; Farshad,Mirzavi ^[2] ; Hammed Tanimowo,Aiyelabegan ^[3] ; Anvar,Soleimani ^[4] ; Jamshid,Gholizadeh Navashenaq ^[5] ; Iman,Karimi-Sani ^[6] ; Abolfazl,Rafati Zomorodi ^[7] ; Roghayyeh,Vakili-Ghartavol ^[8]

作者单位： Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran. ^[1] Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran. ^[2] Department of Biochemistry, Kwara State University, Malete, Nigeria. ^[3] Department of Medical Microbiology, College of Health Sciences, Cihan University-Sulaimaniya, Sulaimaniya, 46001, Kurdistan Region, Iraq. ^[4] Noncommunicable Diseases Research Center, Bam University of Medical Sciences, Bam, Iran. ^[5] Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran. ^[6] Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. ^[7] Department of Medical Nanotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran; Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: Roghayyehvakili@sums.ac.ir. ^[8]

关键词 Bacterial infection Drug delivery Microbial resistance Nanotechnology